NRX Pharmaceuticals Inc. Common Stock (NASDAQ: NRXP)
Company Name:NRX Pharmaceuticals Inc. Common Stock
Stock Symbol:NASDAQ: NRXP
Class Period Start:06/01/2021
Class Period End (inclusive):11/04/2021
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the ZYESAMI EUA Application contained insufficient data regarding the potential benefits and risks of ZYESAMI; (ii) accordingly, the FDA was unlikely to approve the ZYESAMI EUA Application in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.